

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)



(10) International Publication Number
WO 2025/125545 A1

(51) International Patent Classification:

C07K 16/00 (2006.01) C07K 16/32 (2006.01)
C07K 16/24 (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(21) International Application Number:

PCT/EP2024/086172

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

13 December 2024 (13.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23315455.8 15 December 2023 (15.12.2023) EP

(71) Applicant: **SANOFI** [FR/FR]; 46 avenue de la Grande Armée, 75017 Paris (FR).

(72) Inventors: **LANGE, Christian**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).
LANGER, Thomas; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **RAO, Ercole**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).

(74) Agent: **SCHIENER, Jens**; Zwicker Schnappauf & Partner Patentanwälte PartG mbB, Hansastr. 32, 80686 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: EFFECTORLESS IGG1 FC VARIANTS

(57) Abstract: The present invention relates to IgG1 Fc variants which do not elicit antibody effector functions, such as CDC, ADCP and ADCC. In particular, the present invention relates to IgG1 Fc variant polypeptides which comprise the mutations L234A, L235A, A327G, P329A, A330S, and P331S, according to EU numbering, molecules comprising such IgG1 Fc variant polypeptides and uses of such molecules to reduce antibody effector function.

WO 2025/125545 A1